Mavacamten

Highest phase reached
Approved
www.ebi.ac.uk
Drug type
Small molecule
www.ebi.ac.uk
First approval year
2022
www.ebi.ac.uk

First approval year
2022
www.ebi.ac.uk
Listing at source
Listed
Highest phase reached
Approved
www.ebi.ac.uk

Drug type
Small molecule
www.ebi.ac.uk
Drug name
Mavacamten
www.ebi.ac.uk
Molecular weight
273.34
www.ebi.ac.uk
Structure (SMILES)
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
www.ebi.ac.uk

  • camzyos
  • Camzyos

  • camzyos
  • Camzyos
  • Camzyos (Mavacamten)
  • camzyos mavacamten
  • mavacamten
  • Mavacamten
  • Mavacamten [INN]
  • Mavacamten [MI]
  • Mavacamten [USAN]
  • Mavacamten [WHO-DD]
  • mavacamten inn
  • mavacamten mi
  • mavacamten usan
  • mavacamten who dd
  • myk 461
  • Myk-461
  • MYK-461
  • sar 439152
  • SAR-439152

CAS registry numbers
  • 1642288-47-8
ChEMBL ID
CHEMBL4297517
www.ebi.ac.uk
InChIKey
RLCLASQCAPXVLM-NSHDSACASA-N
www.ebi.ac.uk
PubChem compound IDs
  • 117761397
RxNorm IDs (RxCUI)
  • 2600867
FDA ingredient codes (UNII)
  • QX45B99R3J

  • C01EB
  • C01EB24
Sources for recorded values
www.ebi.ac.uk

Applicant
BRISTOL
Approval date
28 Apr 2022
Application number
NDA214998

Status
Authorised
Status date
26 Jun 2023
Authorisation date
26 Jun 2023
Approved indications
Treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Product number
EMEA/H/C/005457
Authorisation holder
Bristol-Myers Squibb Pharma EEIG
Priority medicines scheme
No
Generic
No
Biosimilar
No
Generic medicines
0
Biosimilar medicines
0
Advanced therapy
No
Conditional approval
No
Additional monitoring
Yes
Accelerated assessment
No
Exceptional circumstances
No

Therapeutic areas

  • Cardiomyopathy, Hypertrophic
European medicines record
www.ema.europa.eu

Patents
2
Designations
4
Earliest recorded loss of exclusivity
28 Apr 2036
First in class
Yes
Fast track
No
Breakthrough designation
Yes
Orphan designation
No
Priority review
No
Orphan exclusivity
No
Accelerated approval
No
Availability
Prescription only
Boxed warning
Yes

Pharmacology name
mavacamten
Type
Synthetic organic
Drug name stem
-camten
Approval recorded by Guide to Pharmacology
Yes

Administration routes

  • Oral

  • Mechanism
    Cardiac myosin inhibitor
    Action type
    Inhibitor
    Target
    Cardiac myosin
    Protein identifier
    A7E2Y1
  • Mechanism
    Cardiac myosin inhibitor
    Action type
    Inhibitor
    Target
    Cardiac myosin
    Protein identifier
    P08590
  • Mechanism
    Cardiac myosin inhibitor
    Action type
    Inhibitor
    Target
    Cardiac myosin
    Protein identifier
    P10916
  • Mechanism
    Cardiac myosin inhibitor
    Action type
    Inhibitor
    Target
    Cardiac myosin
    Protein identifier
    P12829
  • Mechanism
    Cardiac myosin inhibitor
    Action type
    Inhibitor
    Target
    Cardiac myosin
    Protein identifier
    P12883
  • Mechanism
    Cardiac myosin inhibitor
    Action type
    Inhibitor
    Target
    Cardiac myosin
    Protein identifier
    P13533
  • Mechanism
    Cardiac myosin inhibitor
    Action type
    Inhibitor
    Target
    Cardiac myosin
    Protein identifier
    Q01449

Open Targets mechanisms

  • Mechanism
    Cardiac myosin inhibitor
    Action type
    Inhibitor
    Target
    Cardiac myosin

  • Condition
    Cardiovascular Diseases
    Highest recorded phase
    4
    Condition identifier
    EFO:0000319
    Subject identifier
    D002318
  • Condition
    Cardiomyopathy, Hypertrophic
    Highest recorded phase
    4
    Condition identifier
    EFO:0000538
    Subject identifier
    D002312
  • Condition
    Heart Failure
    Highest recorded phase
    2
    Condition identifier
    EFO:0003144
    Subject identifier
    D006333

  • Condition identifier
    EFO_0000319
  • Condition identifier
    EFO_0000538
  • Condition identifier
    EFO_0000556
  • Condition identifier
    EFO_0003144
    Highest recorded phase
    2
  • Condition identifier
    HP_0000822
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0004995
    Highest recorded phase
    4
  • Condition identifier
    MONDO_0005045
    Highest recorded phase
    4
  • Condition identifier
    MONDO_0005252
    Highest recorded phase
    2

Warnings

  • Warning
    Black Box Warning
    Effect
    cardiotoxicity

Open Targets warnings

  • Warning
    Black Box Warning
    Effect
    cardiotoxicity
    Country
    United States

  • Event
    anticholinergic effect
    Reports
    2
    Reporting signal score
    22.0102
  • Event
    drug interaction
    Reports
    9
    Reporting signal score
    20.1075
  • Event
    left ventricular dysfunction
    Reports
    3
    Reporting signal score
    12.4393
  • Event
    left ventricular outflow tract gradient increased
    Reports
    1
    Reporting signal score
    10.989

Dose
5 mg
Route
Oral
How often
Once daily

Hydrogen bond acceptors
4
Hydrogen bond donors
2
Polar surface area
66.89
Calculated partition coefficient (ALogP)
2.29
Calculated partition coefficient (XLogP)
2.1
Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Rule-of-five violations
0
Rotatable bonds
4
Heavy atoms
20
Molecular formula
C15H19N3O2
Monoisotopic mass
273.147726857
Natural product
No

  • 73625-111
  • 73625-112
  • 73625-113
  • 73625-114

Recorded assays
52
Active assays
12

Active assay types

  • Confirmatory

Liver toxicity assay

Median
3,650
Mean
3,650
Minimum
2,200
Maximum
5,100
Unit
nM
Assays
2
Standard deviation
2,050.61
Summary method
median
Censored results excluded
0
Other units excluded
0
Unknown units excluded
0

Measurement types

  • EC50

Related records

Trials (41)

Approved for (2)

In development for (1)

Targets (7)